Valuation: CS Diagnostics Corp.

Market Cap 17.5M 15.2M 14.12M 13.02M 24.52M 1.67B 24.96M 167M 65.43M 830M 65.72M 64.28M 2.79B P/E 2024
232,000x
P/E 2025 1,077x
Enterprise Value 17.49M 15.19M 14.11M 13.01M 24.51M 1.67B 24.96M 167M 65.4M 829M 65.69M 64.25M 2.79B EV / Sales 2024
1,357x
EV / Sales 2025 375x
Free-Float
14.55%
Yield 2024 *
-
Yield 2025 -
1 day-4.41%
1 week+11.11%
Current month+96.97%
1 month+96.97%
3 months-48.21%
6 months-72.92%
Current year-78.75%
1 week 0.03
Extreme 0.03
0.07
1 month 0.01
Extreme 0.0105
0.14
Current year 0.01
Extreme 0.0105
0.4
1 year 0.01
Extreme 0.0105
0.4
3 years 0.01
Extreme 0.0105
6.2
5 years 0.01
Extreme 0.0105
9
10 years 0.01
Extreme 0.0105
28.95
Manager TitleAgeSince
Chief Executive Officer 56 31/03/2022
Director of Finance/CFO 47 31/12/2021
Corporate Officer/Principal 45 17/07/2024
Director TitleAgeSince
Chairman 56 24/09/1996
Director/Board Member 47 31/12/2021
Director/Board Member 54 31/08/2025
Date Insider Type Main position Quantity % Market Cap.
31/12/25 Other

Chief Executive Officer

49,362,500 35.9418%
31/12/25 Other

Chief Executive Officer

104,507,800 76.0941%
31/12/25 Other

Chief Executive Officer

42,560,096 30.9888%
Change 5-day change 1-year change 3-year change Capi.($)
-4.41%+11.11%-13.33%-96.39% 17.5M
-2.21%+4.82%-17.85%-6.32% 187B
-2.09%+4.51%-6.47%-2.88% 112B
-2.00%+2.35%+7.00%+67.36% 61.99B
+2.75%-0.10%+27.92%+48.43% 48.52B
-1.75%+8.16%-8.86%-40.98% 46.4B
-2.40%+3.96% - - 33.89B
-0.80%+5.76%-16.30%-43.69% 28.99B
+0.63%-4.47%+36.27%-7.08% 23.75B
-1.54%+9.77%+0.85%+0.51% 22.89B
Average -1.37%+3.92%+1.02%-9.00% 56.54B
Weighted average by Cap. -1.48%+5.54%-4.28%+3.19%

Financials

2024 2025
Net sales 111K 96.34K 89.46K 82.5K 155K 10.59M 158K 1.06M 415K 5.26M 417K 407K 17.68M 204K 177K 165K 152K 286K 19.48M 291K 1.95M 763K 9.67M 766K 749K 32.53M
Net income 761 661 613.82 566.09 1.07K 72.65K 1.09K 7.27K 2.85K 36.08K 2.86K 2.8K 121K 71.22K 61.86K 57.45K 52.98K 99.79K 6.8M 102K 680K 266K 3.38M 267K 262K 11.36M
Net Debt -501 -435.17 -404.11 -372.68 -702.01 -47.83K -714.73 -4.78K -1.87K -23.75K -1.88K -1.84K -79.89K -6.81K -5.92K -5.5K -5.07K -9.55K -650K -9.72K -65.06K -25.47K -323K -25.58K -25.02K -1.09M
Logo CS Diagnostics Corp.
CS Diagnostics Corp is a Germany-based medical technology and distribution company. The Company is focused on developing and commercializing therapeutic and preventive solutions to improve patient care and outcomes. Its primary products are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a surface disinfectant. CS Protect Hydrogel is an injectable organ spacer initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. It is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. MEDUSA’s formulation provides an extended duration of antimicrobial protection on surfaces. It includes color-changing test strips that allow users to verify the concentration of the active ingredient over time.
Employees
1
Date Price Change Volume
29/07/26 US$0.0700 -.--% 2,000
28/07/26 US$0.0700 -.--% 10,100
  1. Stock Market
  2. Stocks
  3. CSDX Stock